Danaher Corp.

Danaher designs, manufactures and markets medical, industrial and commercial products and services, the company has four segments: Life Sciences, which provides research tools to study the basic building blocks of life, including genes and proteins; Diagnostics, which provides analytical instruments, reagents, consumables, software and services to hospitals, physicians' offices, and reference laboratories; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone; and Environmental and Applied Solutions, which provides products and services that help protect resources and keep global food and water supplies safe.
  • TickerDHR
  • ISINUS2358511028
  • ExchangeNew York Stock Exchange
  • SectorGeneral Industrials
  • CountryUnited States

Danaher Corp: 2 directors sold after exercising options/sold

Two Directors at Danaher Corp sold after exercising options/sold 83,982 shares at between 198.556USD and 199.091USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

Danaher Corporation - April 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-term ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-term ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Danaher Corp: 2 directors sold after exercising options/sold

Two Directors at Danaher Corp sold after exercising options/sold 83,982 shares at between 198.556USD and 199.091USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

MarketLine Department

Ing Groep N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Ing Groep N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ing Groep N.V. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. KeyHighl...

Valens Research

Valens Equity Insights and Inflections - 2020 01 07

GOOGL currently trades near corporate averages relative to UAFRS-based (Uniform) Earnings, with a 19.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to fade from 26% in 2018 to a historical low of 11% by 2023, accompanied by 22% Uniform Asset growth going forward. However, analysts have less bearish expectations, projecting Uniform ROA to only decline slightly to 21% by 2020, accompanied by 22% Uniform Asset growth. Moreover, management is confident about their product portfolio, revenue growth, and cash flow. Current valuations appear to be pricing in ov...

Valens Research

DHR - Embedded Expectations Analysis - 2020 01 02

Danaher Corporation (DHR:USA) currently trades above recent averages relative to UAFRS-based (Uniform) Earnings, with a 30.1x Uniform P/E. At these levels, markets are pricing in bullish expectations for the firm, but management may be concerned about revenue, Beckman Diagnostics, and municipal spending. Specifically, management may be concerned about the sustainability of recent revenue growth within the Pall business. Additionally, they may be concerned about the sustainability of recent revenue growth rates in their Beckman Diagnostics business and about their ability to continue improving...

Danaher Corporation - April 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Danaher Corporation: Update to credit analysis following downgrade to Baa1 upon close of Cytiva

Danaher's deleveraging path into the low-to-mid 3 times debt/EBITDA range will be slowed by global macroeconomic weakness induced by the ongoing spread of the coronavirus.

Moody's assigns A2 RUR-Down to Danaher's new senior unsecured European notes

Rating Action: Moody's assigns A2 RUR-Down to Danaher's new senior unsecured European notes. Global Credit Research- 25 Mar 2020. New York, March 25, 2020-- Moody's Investors Service assigned an A2 rating, under review for downgrade, to Danaher Corporation's new senior unsecured European notes.

Danaher Corporation - December 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Danaher Corporation - September 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

DANAHER CORP. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of DANAHER CORP. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date February 25, 2020, the closing price was USD 151.65 and its target price was estimated at USD 144.07.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch